Key result
Implementation of a high-sensitivity troponin I assay with sex-specific thresholds increased the incidence of acute myocardial infarction diagnosis but did not reduce the risk of major adverse cardiovascular events.
Why the study?
Using hs-cTn assays with sex-specific 99th percentiles may improve management of patients with suspected AMI, but the impact of transitioning from conventional assays required investigation.
Does implementing a high-sensitivity troponin I assay with sex-specific thresholds improve clinical management and reduce major adverse cardiovascular events in patients with suspected acute coronary syndrome?
Observational (n=12,489)
Yes
Does implementing a high-sensitivity troponin I assay with sex-specific thresholds improve clinical management and reduce major adverse cardiovascular events in patients with suspected acute coronary syndrome?
Implementing a high-sensitivity troponin I assay with sex-specific thresholds increased AMI diagnoses but did not significantly alter clinical management or reduce major adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
Adoption of sex-specific hs-cTnI thresholds raised AMI diagnoses without improving management or prognosis; leaves open net clinical benefit in routine care.
Using high-sensitivity cardiac troponin (hs-cTn) assays with sex-specific 99th percentiles may improve management of patients with suspected acute myocardial infarction (AMI). We investigated the impact of transitioning from a conventional troponin I assay to a high-sensitivity assay with sex-specific thresholds, in patients with suspected acute coronary syndrome admitted to Swedish coronary care units. Based on data from SWEDEHEART registry (females, n = 4,819/males, n = 7,670), we compared periods before and after implementation of hs-cTnI assay (Abbott) using sex-specific 99th percentiles. We investigated differences on discharge diagnosis, in-hospital examinations, treatments, and clinical outcome. Upon implementation of the hs-cTnI assay, proportion of patients with troponin levels above diagnostic AMI threshold increased in women and men by 24.3% versus 14.8%, respectively. Similarly, incidence of AMI increased by 11.5% and 9.8%. Diagnostic interventions and treatments increased regardless of sex. However, these associations did not persist following multivariable adjustment, probably due to the effect of temporal management trends during the observation period. Overall, no risk reduction on major adverse cardiovascular events was observed (HR: 0.91 [95% CI 0.80-1.03], P = 0.126). The implementation of hs-cTnI assay together with sex-specific 99th percentiles was associated with an increase in incidence of AMI regardless of sex, but had no major impact on clinical management and prognosis.
No takes yet. Share an insight, caveat, or question.
Kimenai et al. (2020) conducted an observational in Suspected acute coronary syndrome (n=12,489). High-sensitivity cardiac troponin I (hs-cTnI) assay with sex-specific thresholds vs. Conventional cardiac troponin (cTn) assay was evaluated on Major adverse cardiovascular events (MACE) (HR 0.91, 95% CI 0.80-1.03, p=0.126). Implementation of a high-sensitivity troponin I assay with sex-specific thresholds increased the incidence of acute myocardial infarction diagnosis but did not reduce the risk of major adverse cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: